VHsquared to present new information showing potential of oral anti-TNFα domain antibody, V565, in IBD at 13th ECCO Congress, Vienna, February 14-17 2018

Cambridge, UK, February 7 2018 – VHsquared, the oral domain antibody company, will be presenting significant new information regarding its oral anti-TNFα Vorabody, V565, at the 13th ECCO Congress in Vienna (February 14-17). The poster uses data from two clinical studies with V565 and VHsquared’s proprietary mucosal exposure model to support once-daily dosing in the treatment of IBD.

The poster elucidates the development of the model and demonstrates that the model’s predictions of V565 concentrations are highly concordant with measured concentrations in the GI lumen. The poster also reports the strong suppression of disease-related inflammatory processes in the lamina propria of ulcerative colitis patients achieved by V565 following oral dosing.

**Poster presentation P668:** Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD. *Session: Posters - Clinical: Therapy and Observation, February 16, 12:30 - 13:30, Dr Suhail Nurbhai, VHsquared*

V565 is the lead Vorabody in the VHsquared portfolio, and is currently in an international Phase II trial for Crohn’s disease, HarbOR¹ (V56502). Vorabodies are potent, orally administered protease-resistant domain antibodies generated by VHsquared’s pioneering platform technology. The product has been developed to achieve optimum local concentrations directly at IBD sites in the intestinal tract. It is expected to combine the disease modifying impact of injectable systemic anti-TNFα antibodies in IBD with the benefits of oral administration, with activity targeted to the site of inflammation, negligible systemic exposure and minimal immunogenicity.

---ENDS---

¹A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease, NCT02976129

For more information please contact emma.palmerfoster@vhsquared.com